May 25, 2022--Researched by Industrial Info Resources (Sugar Land, Texas)--While promising to keep the availability of essential drugs needed by Russian citizens, major drug companies have responded to the Ukraine invasion from a financial position. The responses all seem to center on cancelling or halting planned capital investments, along with discontinuation of clinical trials in Russia. Nobody currently in a clinical trial will be abandoned, but no new studies will be started.
Companies featured: Pfizer Incorporated, (NYSE:PFE) (New York, New York), Novartis International AG (NYSE:NVS), Novo Nordisk A/S (NYSE:NVO), Eli Lilly (NYSE:LLY)
This Premium Article can be purchased individually or as part of a subscription
Articles related to this company
Toll Free: +1 800 762 3361
Phone: +1 713 783 5147
Fax: +1 713 266 9306